Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.

Joel Marcus Biography and Net Worth

Mr. Marcus has served on the board of directors of ITCI since April 2006. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the renowned Alexandria Summit in 2011. He is the Executive Chairman of the board of directors of Alexandria. He served as Chairman of Alexandria’s board of directors from May 2007 to April 2018, Chief Executive Officer from March 1997 to April 2018, President from February 2009 to April 2018, and has served as a director since the company’s inception in 1994. In addition to ITCI, Mr. Marcus serves on the boards of Accelerator Life Science Partners and AgTech Accelerator Corporation (Chairman), for which he was one of the original architects and co-founders, Applied Therapeutics Inc., Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Boragen Inc., MeiraGTx Limited, Yumanity Therapeutics; Biotechnology Innovation Organization (BIO), the Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, MassBio, NewYorkBIO, The Scripps Research Institute; the 9/11 Memorial & Museum, the Navy SEAL Foundation, the Partnership for New York City, and Robin Hood Foundation, as well as on Nareit’s 2018 Executive Board.

Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with a unique expertise in the biopharmaceutical industry, and was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs.

Mr. Marcus earned his undergraduate and Juris Doctor degrees at the University of California, Los Angeles, and was a recipient of the EY Entrepreneur Of the Year Award (Los Angeles – Real Estate).

What is Joel S. Marcus' net worth?

The estimated net worth of Joel S. Marcus is at least $2.42 million as of May 12th, 2022. Mr. Marcus owns 54,233 shares of Intra-Cellular Therapies stock worth more than $2,417,707 as of September 28th. This net worth approximation does not reflect any other assets that Mr. Marcus may own. Learn More about Joel S. Marcus' net worth.

How do I contact Joel S. Marcus?

The corporate mailing address for Mr. Marcus and other Intra-Cellular Therapies executives is 430 EAST 29TH STREET, NEW YORK NY, 10016. Intra-Cellular Therapies can also be reached via phone at (464) 440-9333 and via email at [email protected] Learn More on Joel S. Marcus' contact information.

Has Joel S. Marcus been buying or selling shares of Intra-Cellular Therapies?

Joel S. Marcus has not been actively trading shares of Intra-Cellular Therapies during the past quarter. Most recently, Joel S. Marcus sold 10,000 shares of the business's stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $55.00, for a transaction totalling $550,000.00. Following the completion of the sale, the director now directly owns 54,233 shares of the company's stock, valued at $2,982,815. Learn More on Joel S. Marcus' trading history.

Who are Intra-Cellular Therapies' active insiders?

Intra-Cellular Therapies' insider roster includes Christopher Alafi (Director), Suresh Durgam (Insider), Michael Halstead (EVP), Lawrence Hineline (CFO), Joel Marcus (Director), Sharon Mates (CEO), Mark Neumann (EVP), and Rory Riggs (Director). Learn More on Intra-Cellular Therapies' active insiders.

Are insiders buying or selling shares of Intra-Cellular Therapies?

During the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 894,792 shares worth more than $44,899,132.44. The most recent insider tranaction occured on September, 21st when CFO Lawrence J. Hineline sold 65,164 shares worth more than $2,973,433.32. Insiders at Intra-Cellular Therapies own 3.7 % of the company. Learn More about insider trades at Intra-Cellular Therapies.

Information on this page was last updated on 9/21/2022.

Joel S. Marcus Insider Trading History at Intra-Cellular Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Sell10,000$55.00$550,000.0054,233View SEC Filing Icon  
3/7/2022Sell5,000$54.52$272,600.00View SEC Filing Icon  
6/14/2021Sell18,289$42.27$773,076.0313,767View SEC Filing Icon  
5/13/2020Sell7,297$20.63$150,537.1114,374View SEC Filing Icon  
5/11/2020Sell50,000$19.95$997,500.0014,374View SEC Filing Icon  
11/12/2018Sell32,000$18.17$581,440.0021,671View SEC Filing Icon  
11/9/2018Sell25,000$18.24$456,000.0021,671View SEC Filing Icon  
12/8/2015Sell92,700$54.47$5,049,369.0018,722View SEC Filing Icon  
See Full Table

Joel S. Marcus Buying and Selling Activity at Intra-Cellular Therapies

This chart shows Joel S Marcus's buying and selling at Intra-Cellular Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intra-Cellular Therapies Company Overview

Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $44.58
Low: $43.07
High: $44.99

50 Day Range

MA: $52.01
Low: $42.70
High: $59.99

2 Week Range

Now: $44.58
Low: $34.43
High: $66.00


681,697 shs

Average Volume

937,346 shs

Market Capitalization

$4.21 billion

P/E Ratio


Dividend Yield



Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January…

And now, he’s issuing a brand-new warning – along with a unique solution.
Details here.